デフォルト表紙
市場調査レポート
商品コード
1549435

インドのジェネリック医薬品市場の評価:用途別、タイプ別、ブランド別、投与経路別、流通チャネル別、地域別、機会、予測(2018年度~2032年度)

India Generic Drugs Market Assessment, By Application, By Type, By Brand, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, FY2018-FY2032F


出版日
ページ情報
英文 122 Pages
納期
3~5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.26円
インドのジェネリック医薬品市場の評価:用途別、タイプ別、ブランド別、投与経路別、流通チャネル別、地域別、機会、予測(2018年度~2032年度)
出版日: 2024年09月06日
発行: Market Xcel - Markets and Data
ページ情報: 英文 122 Pages
納期: 3~5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

インドのジェネリック医薬品の市場規模は、2024年度の137億1,000万米ドルから2032年度に259億4,000万米ドルに達すると予測され、2025年度~2032年度の予測期間にCAGRで8.29%の成長が見込まれます。市場の成長は、政府による支援政策や取り組みの導入、慢性疾患の有病率の増加、主要市場企業による投資の増加によって支えられています。また、ジェネリック医薬品に関連するさまざまな利点に対する意識の高まりも、インドにおけるジェネリック医薬品需要を後押ししています。ジェネリック医薬品は、費用対効果の高い治療を確実に提供することで、国民の医療需要に対応する一助となっています。

市場の成長は、同国の市場の主要企業による新薬の上市によっても支えられています。2023年1月、Sun Pharmaceutical Industries Ltd.がPfizerの乳がん治療薬パルボシクリブのジェネリック医薬品をインドで発売しました。ジェネリック医薬品の参入は、同社のインドの特許が切れた後に可能となっています。この新薬の発売により、同国における同薬の入手性が確保され、患者の利便性が向上し、インドでもっとも一般的ながんの1つである乳がん対策に寄与することになります。Global Cancer Observatory(GCO)の推計によると、インドでは2022年に約9万8,337人の女性が乳がん関連で死亡しています。

また、主要市場企業は複雑なジェネリック医薬品の開発に向けて積極的に投資しており、研究開発活動にますます力を入れています。ジェネリック医薬品に対する厳しい規制は、患者が頻繁な投薬を必要とする慢性疾患や生涯を通じた疾患に対抗するために不可欠な効果的な治療ソリューションを、入手性を維持しながら利用できるようにします。

慢性疾患の患者の増加が市場需要を押し上げる

糖尿病、がん、神経血管疾患、心血管疾患など、国内におけるさまざまな慢性疾患の罹患率の増加は、市場に有利な成長機会をもたらしています。世界保健機関(WHO)の推計によると、インドでは18歳を超える約7,700万人が2型糖尿病に罹患しており、2,500万人が糖尿病を発症するリスクが高いです。このような疾患の患者の増加に加え、ライフスタイルの変化や高齢化の進行により、医療従事者と患者の双方から好まれる、費用対効果の高い長期投薬が求められており、インドのジェネリック医薬品市場の成長を支えています。

政府の取り組みの増加が市場拡大を支える

製薬部門の研究開発活動を促進する支援政策や取り組みの立ち上げの増加が、インドのジェネリック医薬品の市場規模を押し上げています。2023年9月、世界の医薬品産業における高価値・大量生産の企業への変貌を支援するため、National Policy on Research and Development and Innovation in Pharma-MedTech Sectorが発表されました。この政策は、複雑なジェネリック医薬品、特許切れ間近の医薬品、バイオ医薬品など、特定の高価値製品の生産と投資を強化するよう、国内外の企業にインセンティブを与えることを目的としています。このような取り組みは、複雑なジェネリック医薬品の開発を支援し、市場の拡大にプラスの影響を与えると予測されます。

心血管用途が大きな市場シェアを占める

インドでは心血管疾患の患者数が増加しており、これがインドのジェネリック医薬品市場の需要を押し上げています。2022年2月にClinical Epidemiology and Global Healthに掲載された論文によると、インドにおける心血管疾患の自己申告有病率は45歳以上の成人で29.4%でした。同国における心血管疾患の患者数の増加は、運動不足、高コレステロール、糖尿病に起因すると考えられます。このような増加により、心血管治療薬のジェネリック医薬品への要求が高まっています。ジェネリック医薬品による代替は、費用対効果により患者と医療システムの双方にとって潜在的に重要だからです。さらに、この代替は医薬品支出の価値を向上させます。

当レポートでは、インドのジェネリック医薬品市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢と見通しなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 インドのジェネリック医薬品市場の見通し(2018年度~2032年度)

  • 市場規模の分析と予測
    • 金額
    • 数量
  • 市場シェア分析と予測
    • 用途別
    • タイプ別
    • ブランド別
    • 投与経路別
    • 流通チャネル別
    • 地域別
    • 市場シェア分析:企業別(金額)(上位5社とその他 - 2024年度)
  • 市場マップ分析(2024年度)
    • 用途別
    • タイプ別
    • ブランド別
    • 投与経路別
    • 流通チャネル別
    • 地域別

第5章 需給分析

第6章 輸入と輸出の分析

第7章 バリューチェーン分析

第8章 ポーターのファイブフォース分析

第9章 PESTLE分析

第10章 価格分析

第11章 市場力学

  • 市場促進要因
  • 市場の課題

第12章 市場の動向と発展

第13章 規制枠組みとイノベーション

  • バイオアベイラビリティ/生物学的同等性試験
  • 規制当局の承認

第14章 特許の有効期限

第15章 ケーススタディ

第16章 競合情勢

  • マーケットリーダー上位5社の競合マトリクス
  • 上位5社のSWOT分析
  • 主要企業上位10社の情勢
    • Aurobindo Pharmaceuticals
    • Sun Pharmaceutical Industries Ltd.
    • Cipla Ltd.
    • Dr. Reddy's Laboratories
    • Teva Pharmaceuticals Industries Ltd.
    • Lupin Ltd.
    • Zydus Group
    • Novartis AG
    • Fresenius Kabi India Pvt. Ltd.
    • Viatris Inc.

第17章 戦略的推奨

第18章 当社について、免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. India Generic Drugs Market, By Value, In USD Billion, FY2018-FY2032F
  • Figure 2. India Generic Drugs Market, By Volume, In Number of Prescriptions, FY2018-FY2032F
  • Figure 3. India Generic Drugs Market Share (%), By Application, FY2018-FY2032F
  • Figure 4. India Generic Drugs Market Share (%), By Type, FY2018-FY2032F
  • Figure 5. India Generic Drugs Market Share (%), By Brand, FY2018-FY2032F
  • Figure 6. India Generic Drugs Market Share (%), By Route of Administration, FY2018-FY2032F
  • Figure 7. India Generic Drugs Market Share (%), By Distribution Channel, FY2018-FY2032F
  • Figure 8. India Generic Drugs Market Share (%), By Region, FY2018-FY2032F
  • Figure 9. By Application Map-Market Size (USD Billion) & Growth Rate (%), FY2024
  • Figure 10. By Type Map-Market Size (USD Billion) & Growth Rate (%), FY2024
  • Figure 11. By Brand Map-Market Size (USD Billion) & Growth Rate (%), FY2024
  • Figure 12. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), FY2024
  • Figure 13. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), FY2024
  • Figure 14. By Region Map-Market Size (USD Billion) & Growth Rate (%), FY2024
目次
Product Code: MX11866

India generic drugs market is projected to witness a CAGR of 8.29% during the forecast period FY2025-FY2032, growing from USD 13.71 billion in FY2024 to USD 25.94 billion in FY2032. The market's growth is supported by the introduction of supportive government policies and initiatives, the increasing prevalence of chronic diseases, and rising investments by the key market players. The growing awareness about the various advantages associated with generic drugs is also propelling the demand for generic drugs in India. Generic drugs aid in addressing the healthcare requirements of the country's population by ensuring the availability of cost-effective treatments.

The growth of the market is also supported by novel drug launches by the key players of the market in the country. In January 2023, Sun Pharmaceutical Industries Ltd. launched the generic version of palbociclib, Pfizer Inc.'s breast cancer medicine, in India. The entry of the generic version of the drug was possible after the expiration of the company's Indian patent on the product. This launch ensured the affordability of the drug in the country, aiding in improving patient accessibility and combating breast cancer, which is one of the most common forms of cancer in India. As per the estimates of the Global Cancer Observatory (GCO), India had approximately 98,337 female deaths related to breast cancer in 2022.

Additionally, the key market players are actively investing towards the development of complex generic drugs and increasingly focusing on research and development activities. The stringent regulations for generic drugs ensure the availability of effective therapeutic solutions while maintaining their affordability, which is essential for combating chronic and lifelong diseases in which the patient requires frequent doses of medications.

Rising Cases of Chronic Diseases Boosts Market Demand

The increasing incidence of various chronic diseases in the country, including diabetes, cancer, neurovascular diseases, and cardiovascular diseases, among others, are providing lucrative growth opportunities to the market. The World Health Organization (WHO) estimates that approximately 77 million individuals above the age of 18 in India suffer from type 2 diabetes, and 25 million are at a greater risk of developing diabetes. The rising cases of such diseases, coupled with changing lifestyles and the expansion of the aging population, are propelling the requirement for long-term medications that are cost-effective and are preferred by both healthcare providers and patients, supporting the India generic drugs market growth.

Increasing Government Initiatives Support Market Expansion

The increasing launch of supportive policies and initiatives to promote research and development activities in the pharmaceutical sector is boosting India's generic drugs market size. In September 2023, the National Policy on Research and Development and Innovation in Pharma-MedTech Sector was launched to support the country's transformation into a high-value and volume player in the global pharmaceuticals industry. The policy aims to incentivize the domestic and global players to enhance production and investments in specific high-value products, including complex generic drugs, drugs nearing patent expiration, and biopharmaceuticals, among others. Such initiatives are expected to support the development of complex generic drugs and positively influence the market's expansion.

Cardiovascular Applications Hold Significant Market Share

The rising cases of cardiovascular diseases in the country are bolstering the India generic drugs market demand. According to an article published in Clinical Epidemiology and Global Health in February 2022, the self-reported prevalence of cardiovascular diseases in India was 29.4% for adults aged 45 and above. The increasing number of cases of cardiovascular diseases in the country can be attributed to a lack of physical activity, high cholesterol, and diabetes. This increase is propelling the requirement for generic versions of cardiovascular drugs as the generic substitutions are potentially important for both patients and the healthcare system due to their cost-effectiveness. Furthermore, the substitution also improves the value of pharmaceutical spending.

Meanwhile, diabetology is expected to witness significant growth in the coming years. The rising cases of diabetes in India can be attributed to the profound lifestyle and environmental changes witnessed by the population. These changes, including rising per capita spending, industrialization, booming culture of eating out, and migration to urban cities, are contributing to the increasing prevalence of diabetes.

Retail Pharmacies Account for Major Market Share

The strong presence of retail pharmacies in the country and the pharmacist's personalized consultation and recommendations are bolstering the segment's expansion. Additionally, these pharmacies provide a wide range of healthcare products and drugs at one location, which in turn enhances consumer convenience. Various retail pharmacy chains are rapidly growing in the country by providing such advantages to customers. For instance, in September 2022, Apollo Pharmacy announced the opening of its 5000th outlet in India.

Meanwhile, online pharmacies are expected to witness significant growth over the forecast period. This growth can be attributed to the convenience, accessibility, and value-added services online pharmacies provide. They eliminate the requirement for physically visiting the store to pick up the medications, while providing overnight shipping and delivery, aiding patients in effectively managing their diseases.

Future Market Scenario (FY2025-FY2032F)

According to the India generic drugs market analysis, the market is expected to witness significant growth in the coming years owing to the rapid expansion of the healthcare sector, increasing prevalence of chronic diseases and disorders, and rising requirements for affordable healthcare solutions. As per the statistical analysis of incidence rates of cancer published in the Indian Journal of Public Health, the burden of cancer is estimated to rise to 2.98 million by 2025 in India. The ongoing investments in research and development and manufacturing activities and the introduction of supportive government policies are also expected to support the growth of the market over the forecast period. Additionally, the increasing focus of various key market players towards the introduction of generic drugs in the country is also supporting the market's expansion. Furthermore, the introduction of various technologies, including 3-D printing, to support the manufacturing of generic drugs is also propelling the share of generic medicines in the country's pharma industry.

Key Players Landscape and Outlook

The growth of the India generic drugs market is supported by the increasing investments by the key players of the market towards the launch of various generic drugs in India. In March 2024, the Zydus Group launched IBYRA, the generic version of Olaparib, which is a PARP inhibitor in India. The drug targets genetic mutations that are present in different cancer types, allowing for more effective and tailored treatment approaches. Cancer patients who have been diagnosed with BRACA and HRD-positive mutations are administered PARP inhibitors to delay the progression of the diseases. To ensure that the correct patient groups have access to IBYRA, Zydus collaborated with MedGenome Inc. for comprehensive HRD testing.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. India Generic Drugs Market Outlook, FY2018-FY2032F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Application
      • 4.2.1.1. Neurovascular
      • 4.2.1.2. Cardiovascular
      • 4.2.1.3. Dermatology
      • 4.2.1.4. Oncology
      • 4.2.1.5. Diabetology
      • 4.2.1.6. Respiratory
      • 4.2.1.7. Others
    • 4.2.2. By Type
      • 4.2.2.1. Biosimilar Generics
      • 4.2.2.2. Small Molecule Generics
    • 4.2.3. By Brand
      • 4.2.3.1. Branded Generic
      • 4.2.3.2. Pure Generic
    • 4.2.4. By Route of Administration
      • 4.2.4.1. Oral
      • 4.2.4.2. Injectable
      • 4.2.4.3. Topical
      • 4.2.4.4. Others
    • 4.2.5. By Distribution Channel
      • 4.2.5.1. Hospital Pharmacy
      • 4.2.5.2. Retail Pharmacy
      • 4.2.5.3. Online Pharmacy
    • 4.2.6. By Region
      • 4.2.6.1. North
      • 4.2.6.2. East
      • 4.2.6.3. West and Central
      • 4.2.6.4. South
    • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2024)
  • 4.3. Market Map Analysis, FY2024
    • 4.3.1. By Application
    • 4.3.2. By Type
    • 4.3.3. By Brand
    • 4.3.4. By Route of Administration
    • 4.3.5. By Distribution Channel
    • 4.3.6. By Region

5. Demand Supply Analysis

6. Import and Export Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

  • 11.1. Market Drivers
  • 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

  • 13.1. Bioavailability/Bioequivalence Studies
  • 13.2. Regulatory Approvals

14. Patent Expiration

15. Case Studies

16. Competitive Landscape

  • 16.1. Competition Matrix of Top 5 Market Leaders
  • 16.2. SWOT Analysis for Top 5 Players
  • 16.3. Key Players Landscape for Top 10 Market Players
    • 16.3.1. Aurobindo Pharmaceuticals
      • 16.3.1.1. Company Details
      • 16.3.1.2. Key Management Personnel
      • 16.3.1.3. Products and Services
      • 16.3.1.4. Financials (As Reported)
      • 16.3.1.5. Key Market Focus and Geographical Presence
      • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 16.3.2. Sun Pharmaceutical Industries Ltd.
    • 16.3.3. Cipla Ltd.
    • 16.3.4. Dr. Reddy's Laboratories
    • 16.3.5. Teva Pharmaceuticals Industries Ltd.
    • 16.3.6. Lupin Ltd.
    • 16.3.7. Zydus Group
    • 16.3.8. Novartis AG
    • 16.3.9. Fresenius Kabi India Pvt. Ltd.
    • 16.3.10. Viatris Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer